Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

SWG Educational Activities

2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:

54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023

ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023

55th General Assembly of ERIC members at…

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

Abstract submission

Abstract procedureThe official abstract submission is closed as of March 1, 2024 (23:59 CET).

Read more

YoungEHA Mentorship Mixer at EHA2024

Hosted by the YoungEHA Committee, the Mentorship Mixer is a pilot event for a potential EHA mentorship program.

Read more